BRPI0818191A2 - métodos para a formação de vasos a partir de uma população de células de perfusato placentário e para o tratamento de um indivíduo tendo uma doença cardíaca ou vascular, distúrbio, condição ou insulficência - Google Patents

métodos para a formação de vasos a partir de uma população de células de perfusato placentário e para o tratamento de um indivíduo tendo uma doença cardíaca ou vascular, distúrbio, condição ou insulficência

Info

Publication number: BRPI0818191A2
Authority: BR; Brazil
Prior art keywords: insulin; vessels; disorder; heart; individual
Prior art date: 2007-09-26

Application number

BRPI0818191A

Other languages

English (en)

Inventor

Rendon Barrigan Henry

Kang Lin

A Heidaran Mohammad

A Voskinarian-Berse Vanessa

Zhang Xiaokui

Original Assignee

Celgene Cellular Therapeutics

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-09-26

Filing date

2008-09-26

Publication date

2017-06-13

2008-09-26 Application filed by Celgene Cellular Therapeutics filed Critical Celgene Cellular Therapeutics

2017-06-13 Publication of BRPI0818191A2 publication Critical patent/BRPI0818191A2/pt

2017-10-03 Publication of BRPI0818191A8 publication Critical patent/BRPI0818191A8/pt

Links

NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 title 2
102000004877 Insulin Human genes 0.000 title 1
108090001061 Insulin Proteins 0.000 title 1
230000015572 biosynthetic process Effects 0.000 title 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
208000035475 disorder Diseases 0.000 title 1
208000019622 heart disease Diseases 0.000 title 1
229940125396 insulin Drugs 0.000 title 1
230000003169 placental effect Effects 0.000 title 1
208000019553 vascular disease Diseases 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/50—Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/069—Vascular Endothelial cells
- C12N5/0692—Stem cells; Progenitor cells; Precursor cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0603—Embryonic cells ; Embryoid bodies
- C12N5/0605—Cells from extra-embryonic tissues, e.g. placenta, amnion, yolk sac, Wharton's jelly
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/069—Vascular Endothelial cells
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/15—Transforming growth factor beta (TGF-β)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/70—Enzymes

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Biomedical Technology (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Biotechnology (AREA)
Zoology (AREA)
Genetics & Genomics (AREA)
Wood Science & Technology (AREA)
Cell Biology (AREA)
Developmental Biology & Embryology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Engineering & Computer Science (AREA)
Microbiology (AREA)
Biochemistry (AREA)
Vascular Medicine (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Reproductive Health (AREA)
Gynecology & Obstetrics (AREA)
Pregnancy & Childbirth (AREA)
Immunology (AREA)
Virology (AREA)
Epidemiology (AREA)
Urology & Nephrology (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

BRPI0818191A 2007-09-26 2008-09-26 Métodos para a formação de vasos a partir de uma população de células de perfusado placentário, e, uso de uma população de células de perfusado placentário e de perfusado placentário humano ou células de perfusado placentário humano BRPI0818191A8 (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US99567907P	2007-09-26	2007-09-26
PCT/US2008/011167 WO2009042201A1 (en)	2007-09-26	2008-09-26	Angiogenic cells from human placental perfusate

Publications (2)

Publication Number	Publication Date
BRPI0818191A2 true BRPI0818191A2 (pt)	2017-06-13
BRPI0818191A8 BRPI0818191A8 (pt)	2017-10-03

Family

ID=40043062

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0818191A BRPI0818191A8 (pt)	2007-09-26	2008-09-26	Métodos para a formação de vasos a partir de uma população de células de perfusado placentário, e, uso de uma população de células de perfusado placentário e de perfusado placentário humano ou células de perfusado placentário humano

Country Status (12)

Country	Link
US (1)	US20090104164A1 (pt)
EP (1)	EP2205719A1 (pt)
JP (6)	JP5703493B2 (pt)
KR (9)	KR20200136051A (pt)
CN (1)	CN101978045A (pt)
AU (1)	AU2008305516A1 (pt)
BR (1)	BRPI0818191A8 (pt)
CA (1)	CA2700613C (pt)
IL (4)	IL204762A0 (pt)
MX (1)	MX2010003217A (pt)
RU (1)	RU2010116271A (pt)
WO (1)	WO2009042201A1 (pt)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7311905B2 (en) *	2002-02-13	2007-12-25	Anthrogenesis Corporation	Embryonic-like stem cells derived from post-partum mammalian placenta, and uses and methods of treatment using said cells
MXPA03005014A (es) *	2000-12-06	2004-09-10	Robert J Hariri	Metodo para recolectar celulas madres de la placenta.
US20080152629A1 (en) *	2000-12-06	2008-06-26	James Edinger	Placental stem cell populations
EP2338983B1 (en)	2001-02-14	2015-10-07	Anthrogenesis Corporation	Renovation and repopulation of decellularized tissues and cadaveric organs by stem cells
US7498171B2 (en) *	2002-04-12	2009-03-03	Anthrogenesis Corporation	Modulation of stem and progenitor cell differentiation, assays, and uses thereof
AU2003298775B2 (en) *	2002-11-26	2008-07-17	Anthrogenesis Corporation	Cytotherapeutics, cytotherapeutic units and methods for treatments using them
GB0321337D0 (en) *	2003-09-11	2003-10-15	Massone Mobile Advertising Sys	Method and system for distributing advertisements
JP2007531116A (ja) *	2004-03-26	2007-11-01	セルジーン・コーポレーション	幹細胞バンクを提供するためのシステム及び方法
EP1957633B1 (en)	2005-10-13	2013-12-18	Anthrogenesis Corporation	Immunomodulation using placental stem cells
AU2006304274B2 (en) *	2005-10-13	2012-08-16	Celularity Inc.	Production of oligodendrocytes from placenta-derived stem cells
KR20180105266A (ko)	2005-12-29	2018-09-27	안트로제네시스 코포레이션	태반 줄기 세포 집단
US9598669B2 (en)	2005-12-29	2017-03-21	Anthrogenesis Corporation	Composition for collecting placental stem cells and methods of using the composition
AU2006332679A1 (en) *	2005-12-29	2007-07-12	Anthrogenesis Corporation	Co-culture of placental stem cells and stem cells from a second source
US7993918B2 (en)	2006-08-04	2011-08-09	Anthrogenesis Corporation	Tumor suppression using placental stem cells
NZ606814A (en)	2006-10-23	2014-10-31	Anthrogenesis Corp	Methods and compositions for treatment of bone defects with placental cell populations
JP2010518812A (ja) *	2007-02-12	2010-06-03	アンスロジェネシスコーポレーション	接着性胎盤幹細胞由来の肝細胞および軟骨細胞、ならびにｃｄ３４＋、ｃｄ４５−胎盤幹細胞の濃縮細胞集団
CN103356710A (zh)	2007-02-12	2013-10-23	人类起源公司	利用胎盘干细胞治疗炎性疾病
US9200253B1 (en)	2007-08-06	2015-12-01	Anthrogenesis Corporation	Method of producing erythrocytes
KR20200136051A (ko) *	2007-09-26	2020-12-04	안트로제네시스 코포레이션	인간 태반 관류액으로부터의 혈관형성 세포
EP2203176B1 (en)	2007-09-28	2014-11-26	Anthrogenesis Corporation	Tumor suppression using human placental perfusate and human placenta-derived intermediate natural killer cells
CA2734237C (en) *	2008-08-20	2019-07-02	Anthrogenesis Corporation	Treatment of stroke using isolated placental cells
NZ591292A (en)	2008-08-20	2012-10-26	Anthrogenesis Corp	Improved cell composition and methods of making the same
SI2331109T1 (sl)	2008-08-22	2013-10-30	Anthrogenesis Corporation	Postopki in sestavki za zdravljenje okvar kosti s populacijami placentarnih celic
WO2010059828A1 (en)	2008-11-19	2010-05-27	Anthrogenesis Corporation	Amnion derived adherent cells
EP2449095A1 (en) *	2009-07-02	2012-05-09	Anthrogenesis Corporation	Method of producing erythrocytes without feeder cells
US9163212B2 (en)	2010-01-25	2015-10-20	Warsaw Orthopedic, Inc.	Osteogenic cell delivery matrix
CA2787992A1 (en)	2010-01-26	2011-08-04	Anthrogenesis Corporation	Treatment of bone-related cancers using placental stem cells
WO2011103462A1 (en)	2010-02-18	2011-08-25	Osiris Therapeutics, Inc.	Methods of manufacture of immunocompatible amniotic membrane products
PL2556145T3 (pl)	2010-04-07	2017-02-28	Anthrogenesis Corporation	Angiogeneza z zastosowaniem łożyskowych komórek macierzystych
KR20130092394A (ko)	2010-04-08	2013-08-20	안트로제네시스 코포레이션	태반 줄기 세포를 사용한 사르코이드증의 치료
US8883210B1 (en)	2010-05-14	2014-11-11	Musculoskeletal Transplant Foundation	Tissue-derived tissuegenic implants, and methods of fabricating and using same
US9352003B1 (en)	2010-05-14	2016-05-31	Musculoskeletal Transplant Foundation	Tissue-derived tissuegenic implants, and methods of fabricating and using same
US10130736B1 (en)	2010-05-14	2018-11-20	Musculoskeletal Transplant Foundation	Tissue-derived tissuegenic implants, and methods of fabricating and using same
MX342995B (es)	2010-07-13	2016-10-21	Anthrogenesis Corp	Métodos de generar células asesinas naturales.
RU2435594C1 (ru) *	2010-10-04	2011-12-10	Федеральное Государственное Учреждение Ростовский научно-исследовательский институт акушерства и педиатрии Федерального агентства по высокотехнологичной медицинской помощи	Способ лечения плацентарной недостаточности во ii-iii триместрах беременности
US8969315B2 (en)	2010-12-31	2015-03-03	Anthrogenesis Corporation	Enhancement of placental stem cell potency using modulatory RNA molecules
DK2714059T3 (en)	2011-06-01	2019-01-21	Celularity Inc	TREATMENT OF PAIN WHEN USING PLACENT STAM CELLS
WO2013055476A1 (en)	2011-09-09	2013-04-18	Anthrogenesis Corporation	Treatment of amyotrophic lateral sclerosis using placental stem cells
AU2013204922B2 (en)	2012-12-20	2015-05-14	Celgene Corporation	Chimeric antigen receptors
EP3622960A1 (en)	2013-02-05	2020-03-18	Celularity, Inc.	Natural killer cells from placenta
JP6571537B2 (ja) *	2013-03-13	2019-09-04	ザユニバーシティーオブクイーンズランド	療法および予防のための細胞を単離する方法
EP2970372B1 (en)	2013-03-15	2020-09-30	Celgene Corporation	Modified t lymphocytes
HK1221402A1 (zh)	2013-04-02	2017-06-02	University Of Florida Research Foundation, Inc.	用於诱导并调节血管生成的组合物和方法以及用於鉴别血管生成调节剂的方法和实验
CN105916521A (zh) *	2013-11-15	2016-08-31	人类起源公司	包含人胎盘灌注液细胞、其亚群的组合物及其用途
CN103756965B (zh) *	2014-01-27	2016-04-06	山东省齐鲁干细胞工程有限公司	一种从胎盘中灌洗造血干细胞的方法
CN104152405B (zh) *	2014-08-15	2016-06-29	博雅干细胞科技有限公司	从胎盘中分离提取造血干细胞的方法
CA2986702C (en)	2015-05-21	2023-04-04	David Wang	Modified demineralized cortical bone fibers
US20180216065A1 (en) *	2015-07-20	2018-08-02	The Catholic University Of Korea Industry-Academic Cooperation Foundation	Method for Inducing Differentiation of Myeloid-Derived Suppressor Cells from Cord - Blood CD34 Positive Cells and Proliferating Same, and use of Myeloid-Derived
JP6648259B2 (ja) *	2015-08-12	2020-02-14	チャバイオテックカンパニーリミテッド	向上された臍帯由来付着型幹細胞、その製造方法及びその用途
US12551509B2 (en)	2015-11-18	2026-02-17	Lucina Patent Holdco, Llc	Acellular regenerative products and methods of their manufacture
EA201991371A1 (ru) *	2016-12-05	2019-12-30	Селулэрити, Инк.	Лечение лимфедемы и связанных состояний с использованием плацентарных адгезивных клеток
CN107058224B (zh) *	2017-02-10	2020-08-21	广东唯泰生物科技有限公司	一种以胎盘为来源的造血干细胞提取及冻存方法
WO2020113182A1 (en)	2018-11-30	2020-06-04	Celularity, Inc.	Expansion of natural killer cells and ilc3 cells with novel aromatic compounds
CN109652372A (zh) *	2019-01-09	2019-04-19	陕西九州细胞基因工程有限公司	一种人胎盘组织源造血干细胞的快速分离、制备方法
JP6977969B2 (ja) *	2019-03-22	2021-12-08	株式会社ガイアバイオメディシン	免疫細胞提供システム
US20220265712A1 (en)	2019-06-14	2022-08-25	Celularity Inc.	Populations of natural killer cells for treating cancers
US20220273716A1 (en)	2019-07-25	2022-09-01	Celularity Inc.	Populations of natural killer cells comprising a cd38 chimeric antigen receptor
US20230355759A1 (en)	2019-07-31	2023-11-09	Celularity Inc.	Populations of natural killer cells comprising a cleavage resistant cd16
WO2021113849A1 (en)	2019-12-05	2021-06-10	Celularity Inc.	Her2+ cancer treatment with populations of natural killer cells comprising a cleavage resistant cd16
WO2021155312A1 (en)	2020-01-29	2021-08-05	Celularity Inc.	Placental derived natural killer cells for treatment of coronavirus infections
WO2023278628A1 (en)	2021-06-29	2023-01-05	Celularity Inc.	Human placental hematopoietic stem cell derived natural killer cells in acute myeloid leukemia (aml) remission with minimal residual disease (mrd) or relapsed/refractory aml
US20250276063A1 (en)	2021-07-29	2025-09-04	Celularity Inc.	Placenta-dervied nk cells as a senol ytic for therapeutic and other uses
CA3247919A1 (en)	2022-01-11	2023-07-20	Celularity Inc.	CD16 CLEFT-RESISTANT CONSTRUCTIONS AND THEIR USES

Family Cites Families (99)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3862002A (en) *	1962-05-08	1975-01-21	Sanfar Lab Inc	Production of physiologically active placental substances
US5863531A (en) *	1986-04-18	1999-01-26	Advanced Tissue Sciences, Inc.	In vitro preparation of tubular tissue structures by stromal cell culture on a three-dimensional framework
US5004681B1 (en) *	1987-11-12	2000-04-11	Biocyte Corp	Preservation of fetal and neonatal hematopoietic stem and progenitor cells of the blood
US5192553A (en) *	1987-11-12	1993-03-09	Biocyte Corporation	Isolation and preservation of fetal and neonatal hematopoietic stem and progenitor cells of the blood and methods of therapeutic use
US5605822A (en) *	1989-06-15	1997-02-25	The Regents Of The University Of Michigan	Methods, compositions and devices for growing human hematopoietic cells
US5464764A (en) *	1989-08-22	1995-11-07	University Of Utah Research Foundation	Positive-negative selection methods and vectors
US5061620A (en) *	1990-03-30	1991-10-29	Systemix, Inc.	Human hematopoietic stem cell
US5486359A (en) *	1990-11-16	1996-01-23	Osiris Therapeutics, Inc.	Human mesenchymal stem cells
US6010696A (en) *	1990-11-16	2000-01-04	Osiris Therapeutics, Inc.	Enhancing hematopoietic progenitor cell engraftment using mesenchymal stem cells
US5733542A (en) *	1990-11-16	1998-03-31	Haynesworth; Stephen E.	Enhancing bone marrow engraftment using MSCS
US5197985A (en) *	1990-11-16	1993-03-30	Caplan Arnold I	Method for enhancing the implantation and differentiation of marrow-derived mesenchymal cells
DE69431473T2 (de) *	1993-03-31	2003-08-07	Pro-Neuron, Inc.	Inhibitor der stammzellproliferation und seine verwendung
US5709854A (en) *	1993-04-30	1998-01-20	Massachusetts Institute Of Technology	Tissue formation by injecting a cell-polymeric solution that gels in vivo
US5591625A (en) *	1993-11-24	1997-01-07	Case Western Reserve University	Transduced mesenchymal stem cells
US6288030B1 (en) *	1993-12-22	2001-09-11	Amgen Inc.	Stem cell factor formulations and methods
US6174333B1 (en) *	1994-06-06	2001-01-16	Osiris Therapeutics, Inc.	Biomatrix for soft tissue regeneration using mesenchymal stem cells
ES2206509T3 (es) *	1994-06-06	2004-05-16	Case Western Reserve University	Biomatriz para la regeneracion de tejidos.
US6103522A (en) *	1994-07-20	2000-08-15	Fred Hutchinson Cancer Research Center	Human marrow stromal cell lines which sustain hematopoiesis
US5874301A (en) *	1994-11-21	1999-02-23	National Jewish Center For Immunology And Respiratory Medicine	Embryonic cell populations and methods to isolate such populations
US5736396A (en) *	1995-01-24	1998-04-07	Case Western Reserve University	Lineage-directed induction of human mesenchymal stem cell differentiation
US5695998A (en) *	1995-02-10	1997-12-09	Purdue Research Foundation	Submucosa as a growth substrate for islet cells
US6011000A (en) *	1995-03-03	2000-01-04	Perrine; Susan P.	Compositions for the treatment of blood disorders
US5716616A (en) *	1995-03-28	1998-02-10	Thomas Jefferson University	Isolated stromal cells for treating diseases, disorders or conditions characterized by bone defects
US5733541A (en) *	1995-04-21	1998-03-31	The Regent Of The University Of Michigan	Hematopoietic cells: compositions and methods
US5925567A (en) *	1995-05-19	1999-07-20	T. Breeders, Inc.	Selective expansion of target cell populations
US5877299A (en) *	1995-06-16	1999-03-02	Stemcell Technologies Inc.	Methods for preparing enriched human hematopoietic cell preparations
US5858782A (en) *	1995-11-13	1999-01-12	Regents Of The University Of Michigan	Functional human hematopoietic cells
EP0861894B1 (en) *	1995-11-17	2006-03-08	Asahi Kasei Kabushiki Kaisha	Differentiation-suppressive polypeptide
US5716794A (en) *	1996-03-29	1998-02-10	Xybernaut Corporation	Celiac antigen
DE69739540D1 (de) *	1996-04-19	2009-10-01	Osiris Therapeutics Inc	Die wiederherstellung und verstärkung von knochen mittels mesenchymalen stammzellen
US5919176A (en) *	1996-05-14	1999-07-06	Children's Hospital Medical Center Of Northern California	Apparatus and method for collecting blood from an umbilical cord
US5827740A (en) *	1996-07-30	1998-10-27	Osiris Therapeutics, Inc.	Adipogenic differentiation of human mesenchymal stem cells
US5916202A (en) *	1996-08-30	1999-06-29	Haswell; John N.	Umbilical cord blood collection
US6335195B1 (en) *	1997-01-28	2002-01-01	Maret Corporation	Method for promoting hematopoietic and mesenchymal cell proliferation and differentiation
US5879318A (en) *	1997-08-18	1999-03-09	Npbi International B.V.	Method of and closed system for collecting and processing umbilical cord blood
WO1999011287A1 (en) *	1997-09-04	1999-03-11	Osiris Therapeutics, Inc.	Ligands that modulate differentiation of mesenchymal stem cells
DE69922933T2 (de) *	1998-03-13	2005-12-29	Osiris Therapeutics, Inc.	Anwendungen für humane nicht autologe, mesenchymale stammzellen
US6030836A (en) *	1998-06-08	2000-02-29	Osiris Therapeutics, Inc.	Vitro maintenance of hematopoietic stem cells
US6184035B1 (en) *	1998-11-18	2001-02-06	California Institute Of Technology	Methods for isolation and activation of, and control of differentiation from, skeletal muscle stem or progenitor cells
JP3089299B2 (ja) *	1998-12-14	2000-09-18	京都大学長	生体内に毛細血管が豊富な組織を作成するのに用いる新生血管床形成用用具
MXPA01007820A (es) *	1999-02-04	2003-06-19	Technion Res & Dev Foundation	Metodo y aparato para mantenimiento y expansion de celulas de tallo hemopoyeticas y/o celulas progenitoras.
FR2792202B1 (fr) *	1999-04-19	2003-06-13	Pharmascience Lab	Extrait peptidique de lupin et composition pharmaceutique ou cosmetique ou nutraceutique comprenant un tel extrait
US8075881B2 (en) *	1999-08-05	2011-12-13	Regents Of The University Of Minnesota	Use of multipotent adult stem cells in treatment of myocardial infarction and congestive heart failure
US6685936B2 (en) *	1999-10-12	2004-02-03	Osiris Therapeutics, Inc.	Suppressor cells induced by culture with mesenchymal stem cells for treatment of immune responses in transplantation
US20050009876A1 (en) *	2000-07-31	2005-01-13	Bhagwat Shripad S.	Indazole compounds, compositions thereof and methods of treatment therewith
MXPA03005014A (es) *	2000-12-06	2004-09-10	Robert J Hariri	Metodo para recolectar celulas madres de la placenta.
US7311905B2 (en) *	2002-02-13	2007-12-25	Anthrogenesis Corporation	Embryonic-like stem cells derived from post-partum mammalian placenta, and uses and methods of treatment using said cells
US20030045552A1 (en) *	2000-12-27	2003-03-06	Robarge Michael J.	Isoindole-imide compounds, compositions, and uses thereof
EP2338983B1 (en) *	2001-02-14	2015-10-07	Anthrogenesis Corporation	Renovation and repopulation of decellularized tissues and cadaveric organs by stem cells
AU2002251935B2 (en) *	2001-02-14	2007-11-29	Celularity Inc.	Post-partum mammalian placenta, its use and placental stem cells therefrom
CA2396536A1 (en) *	2001-08-10	2003-02-10	Saiko Uchida	Human stem cells originated from human amniotic mesenchymal cell layer
WO2003061591A2 (en) *	2002-01-22	2003-07-31	Advanced Cell Technology, Inc.	Stem cell-derived endothelial cells modified to disrupt tumor angiogenesis
EP1482787A4 (en) *	2002-02-13	2006-02-15	Anthrogenesis Corp	EMBRYONIC TYPE DERIVED STEM CELLS DERIVED FROM MAMMALIAN POST-PARTUM PLACENTA, USES THEREOF, AND METHODS OF TREATMENT BASED ON CELLS OF THIS TYPE
GB0205867D0 (en) *	2002-03-13	2002-04-24	Univ Nottingham	Polymer composite loaded with functioning matter
US20030187515A1 (en) *	2002-03-26	2003-10-02	Hariri Robert J.	Collagen biofabric and methods of preparing and using the collagen biofabric
US7498171B2 (en) *	2002-04-12	2009-03-03	Anthrogenesis Corporation	Modulation of stem and progenitor cell differentiation, assays, and uses thereof
MXPA04011851A (es) *	2002-05-30	2005-03-31	Celgene Corp	Metodos para utilizar inhibidores de jnk o mkk para modular diferenciacion de celula y para tratar desordenes mieloproliferativos y sindromes mielodispl??sticos.
US7422736B2 (en) *	2002-07-26	2008-09-09	Food Industry Research And Development Institute	Somatic pluripotent cells
JP4480128B2 (ja) *	2002-11-20	2010-06-16	独立行政法人科学技術振興機構	マトリックスメタロプロテアーゼ−９の産生を阻害するための薬剤
NZ566132A (en) *	2003-02-13	2009-09-25	Anthrogenesis Corp	Use of umbilical cord blood to treat inflammation, ParkinsonÆs disease or diabetes
ES2569780T3 (es) *	2003-06-27	2016-05-12	DePuy Synthes Products, Inc.	Células posparto derivadas de tejido placentario y métodos de preparación y uso de las mismas
US7569385B2 (en) *	2003-08-14	2009-08-04	The Regents Of The University Of California	Multipotent amniotic fetal stem cells
US20080044392A1 (en) *	2003-10-17	2008-02-21	Innovative Dairy Products Pty Ltd As Trustee For The Participants Of The Coooperative Research Ctr	Isolation of Stem Cell-Like Cells and Use Thereof
EP1699819A2 (en) *	2003-12-29	2006-09-13	Centelion	Treatment of coronary or peripheral ischemia
RU2006144851A (ru) *	2004-06-15	2008-06-20	Бакстер Интернэшнл Инк. (Us)	Применение терапевтических средств ex-vivo в виде твердых микрочастиц
US7147626B2 (en) *	2004-09-23	2006-12-12	Celgene Corporation	Cord blood and placenta collection kit
US7909806B2 (en) *	2004-09-23	2011-03-22	Anthrogenesis Corporation	Cord blood and placenta collection kit
US8017395B2 (en) *	2004-12-17	2011-09-13	Lifescan, Inc.	Seeding cells on porous supports
CA2593549C (en) *	2005-01-07	2016-04-26	Wake Forest University Health Sciences	Regeneration of pancreatic islets by amniotic fluid stem cell therapy
US7642091B2 (en) *	2005-02-24	2010-01-05	Jau-Nan Lee	Human trophoblast stem cells and use thereof
US20060222634A1 (en) *	2005-03-31	2006-10-05	Clarke Diana L	Amnion-derived cell compositions, methods of making and uses thereof
US8367405B2 (en) *	2005-04-12	2013-02-05	Mesoblast, Inc.	Isolation of adult multipotential cells by tissue non-specific alkaline phosphatase
ZA200800144B (en) *	2005-06-10	2010-02-24	Celgene Corp	Human placental collagen compositions, processes for their preparation, methods of their use and kits comprising the compositions
AU2006265601A1 (en) *	2005-06-30	2007-01-11	Anthrogenesis Corporation	Repair of tympanic membrane using placenta derived collagen biofabric
WO2007009062A2 (en) *	2005-07-13	2007-01-18	Anthrogenesis Corporation	Treatment of leg ulcers using placenta derived collagen biofabric
US20070021762A1 (en) *	2005-07-13	2007-01-25	Qing Liu	Ocular plug formed from placenta derived collagen biofabric
WO2007011693A2 (en) *	2005-07-14	2007-01-25	Medistem Laboratories, Inc.	Compositions of placentally-derived stem cells for the treatment of cancer
EP1957633B1 (en) *	2005-10-13	2013-12-18	Anthrogenesis Corporation	Immunomodulation using placental stem cells
CN101437576A (zh) *	2005-12-28	2009-05-20	伊西康公司	使用产后衍生细胞治疗外周血管疾病
KR20180105266A (ko) *	2005-12-29	2018-09-27	안트로제네시스 코포레이션	태반 줄기 세포 집단
US20080064098A1 (en) *	2006-06-05	2008-03-13	Cryo-Cell International, Inc.	Procurement, isolation and cryopreservation of maternal placental cells
US20080050814A1 (en) *	2006-06-05	2008-02-28	Cryo-Cell International, Inc.	Procurement, isolation and cryopreservation of fetal placental cells
CA2654716A1 (en) *	2006-06-09	2007-12-21	Anthrogenesis Corporation	Placental niche and use thereof to culture stem cells
US20090081171A1 (en) *	2006-08-11	2009-03-26	Yu-Show Fu	Cell system for alleviating syndromes of Parkinson's disease in a mammal
WO2008021391A1 (en) *	2006-08-15	2008-02-21	Anthrogenesis Corporation	Umbilical cord biomaterial for medical use
US20080050347A1 (en) *	2006-08-23	2008-02-28	Ichim Thomas E	Stem cell therapy for cardiac valvular dysfunction
NZ606814A (en) *	2006-10-23	2014-10-31	Anthrogenesis Corp	Methods and compositions for treatment of bone defects with placental cell populations
JP2010518812A (ja) *	2007-02-12	2010-06-03	アンスロジェネシスコーポレーション	接着性胎盤幹細胞由来の肝細胞および軟骨細胞、ならびにｃｄ３４＋、ｃｄ４５−胎盤幹細胞の濃縮細胞集団
US20090053182A1 (en) *	2007-05-25	2009-02-26	Medistem Laboratories, Inc.	Endometrial stem cells and methods of making and using same
US20090016999A1 (en) *	2007-07-13	2009-01-15	Michael Cohen	Embryonic cell compositions for wound treatment
MX2008005751A (es) *	2007-09-13	2009-04-16	Clifford L Librach	Metodo de aislamiento y uso de celulas derivadas del tejido del cordon umbilical del primer trimestre.
ES2392729T5 (es) *	2007-09-19	2015-08-28	Pluristem Ltd.	Células adherentes de tejidos adiposos o de placenta y uso de las mismas en terapia
KR20200136051A (ko) *	2007-09-26	2020-12-04	안트로제네시스 코포레이션	인간 태반 관류액으로부터의 혈관형성 세포
NZ591292A (en) *	2008-08-20	2012-10-26	Anthrogenesis Corp	Improved cell composition and methods of making the same
CA2734237C (en) *	2008-08-20	2019-07-02	Anthrogenesis Corporation	Treatment of stroke using isolated placental cells
SI2331109T1 (sl) *	2008-08-22	2013-10-30	Anthrogenesis Corporation	Postopki in sestavki za zdravljenje okvar kosti s populacijami placentarnih celic
CN201299504Y (zh) *	2008-11-11	2009-09-02	薛华	一种方便搭挂的毛巾
EP2449095A1 (en) *	2009-07-02	2012-05-09	Anthrogenesis Corporation	Method of producing erythrocytes without feeder cells
TWI395125B (zh) *	2009-07-14	2013-05-01	Sonix Technology Co Ltd	電容式觸控感應電路

2008
- 2008-09-26 KR KR1020207033934A patent/KR20200136051A/ko not_active Withdrawn
- 2008-09-26 AU AU2008305516A patent/AU2008305516A1/en not_active Abandoned
- 2008-09-26 KR KR1020157020016A patent/KR101645311B1/ko not_active Expired - Fee Related
- 2008-09-26 KR KR1020227028466A patent/KR20220122774A/ko not_active Ceased
- 2008-09-26 KR KR1020107008970A patent/KR101644659B1/ko not_active Expired - Fee Related
- 2008-09-26 EP EP08833350A patent/EP2205719A1/en not_active Withdrawn
- 2008-09-26 CN CN2008801178057A patent/CN101978045A/zh active Pending
- 2008-09-26 JP JP2010526961A patent/JP5703493B2/ja not_active Expired - Fee Related
- 2008-09-26 WO PCT/US2008/011167 patent/WO2009042201A1/en not_active Ceased
- 2008-09-26 MX MX2010003217A patent/MX2010003217A/es not_active Application Discontinuation
- 2008-09-26 KR KR1020167020487A patent/KR20160092062A/ko not_active Ceased
- 2008-09-26 BR BRPI0818191A patent/BRPI0818191A8/pt not_active Application Discontinuation
- 2008-09-26 KR KR1020187015067A patent/KR20180059583A/ko not_active Ceased
- 2008-09-26 CA CA2700613A patent/CA2700613C/en active Active
- 2008-09-26 KR KR1020217028887A patent/KR20210118946A/ko not_active Ceased
- 2008-09-26 KR KR1020207011050A patent/KR20200043517A/ko not_active Withdrawn
- 2008-09-26 KR KR1020197012717A patent/KR20190050867A/ko not_active Ceased
- 2008-09-26 US US12/239,679 patent/US20090104164A1/en not_active Abandoned
- 2008-09-26 RU RU2010116271/10A patent/RU2010116271A/ru not_active Application Discontinuation
2010
- 2010-03-25 IL IL204762A patent/IL204762A0/en active IP Right Grant
2014
- 2014-09-26 JP JP2014196899A patent/JP5985569B2/ja not_active Expired - Fee Related
2015
- 2015-11-17 IL IL242645A patent/IL242645B/en active IP Right Grant
- 2015-11-17 IL IL242644A patent/IL242644B/en active IP Right Grant
2016
- 2016-08-03 JP JP2016152885A patent/JP2017002071A/ja active Pending
2018
- 2018-06-26 IL IL260292A patent/IL260292A/en unknown
- 2018-07-06 JP JP2018129253A patent/JP2018172425A/ja active Pending
2020
- 2020-08-13 JP JP2020136719A patent/JP2020189872A/ja active Pending
2022
- 2022-08-19 JP JP2022131194A patent/JP2022166249A/ja active Pending

Also Published As

Publication number	Publication date
JP2018172425A (ja)	2018-11-08
JP2022166249A (ja)	2022-11-01
BRPI0818191A8 (pt)	2017-10-03
KR20200043517A (ko)	2020-04-27
KR20150090276A (ko)	2015-08-05
CN101978045A (zh)	2011-02-16
WO2009042201A1 (en)	2009-04-02
KR20100091160A (ko)	2010-08-18
KR20220122774A (ko)	2022-09-02
CA2700613A1 (en)	2009-04-02
AU2008305516A1 (en)	2009-04-02
JP5985569B2 (ja)	2016-09-06
KR101644659B1 (ko)	2016-08-01
CA2700613C (en)	2022-09-20
RU2010116271A (ru)	2011-11-10
KR20160092062A (ko)	2016-08-03
JP2020189872A (ja)	2020-11-26
EP2205719A1 (en)	2010-07-14
IL242644B (en)	2018-07-31
KR20190050867A (ko)	2019-05-13
US20090104164A1 (en)	2009-04-23
IL260292A (en)	2018-07-31
KR101645311B1 (ko)	2016-08-03
JP5703493B2 (ja)	2015-04-22
JP2015042648A (ja)	2015-03-05
KR20200136051A (ko)	2020-12-04
IL204762A0 (en)	2010-12-30
MX2010003217A (es)	2010-07-30
JP2010540530A (ja)	2010-12-24
KR20180059583A (ko)	2018-06-04
KR20210118946A (ko)	2021-10-01
IL242645B (en)	2018-07-31
JP2017002071A (ja)	2017-01-05

Legal Events

Date	Code	Title	Description
2017-10-03	B25D	Requested change of name of applicant approved	Owner name: ANTHROGENESIS CORP. (US)
2018-04-17	B06F	Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
2018-06-05	B07D	Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
2018-06-12	B07D	Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
2018-07-31	B07B	Technical examination (opinion): publication cancelled [chapter 7.2 patent gazette]
2019-10-15	B07E	Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
2019-12-24	B06U	Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
2020-05-26	B06A	Patent application procedure suspended [chapter 6.1 patent gazette]
2020-10-20	B09B	Patent application refused [chapter 9.2 patent gazette]
2021-01-05	B09B	Patent application refused [chapter 9.2 patent gazette]	Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL

Publication	Publication Date	Title
BRPI0818191A8 (pt)	2017-10-03	Métodos para a formação de vasos a partir de uma população de células de perfusado placentário, e, uso de uma população de células de perfusado placentário e de perfusado placentário humano ou células de perfusado placentário humano
IL196296A0 (en)	2009-09-22	Manufacture, method, and use of active substance-releasing medical products for permanently keeping blood vessels open
BRPI0914387A2 (pt)	2019-09-24	sistema de tratamento abdominal, método de tratamento de uma cavidade abdominal aberta, e, método de fabricação de um sistema para tratamento de uma cavidade abdominal de um paciente
BRPI0910198A2 (pt)	2016-01-12	composição para administração a partir de um sítio local de um agente baseado em nucleotídeos e método para tratar um sujeito sofrendo de uma doença requerendo tratamento local com um agente baseado em nucleotídeo.
BR112012024267A2 (pt)	2017-12-19	dispositivo médico, conjunto, procedimento médico, método para permanentemente intensificar a circulação sanguínea intracardíaca de um coração de um paciente e meio de leitura
BRPI0817925A2 (pt)	2015-04-07	Sistema e método para monitorar e regular níveis de glicose no sangue em uma corrente sanguiínea
WO2009100137A3 (en)	2009-10-01	Magnetic cells for localizing delivery and tissue repair
BRPI0915105A2 (pt)	2019-09-24	composto de 2,4'-biripidinila como inibidores da proteína cinase d úteis para o tratamento de ia insuficiência cardíaca e cancer
IL178390A0 (en)	2007-03-08	Methods and compositions for the treatment, prevention or management of dysfunctional sleep and dysfunctional sleep associated with disease
DK2375907T3 (da)	2019-06-11	Behandling af sygdomme, lidelser eller tilstande i lungerne under anvendelse af placentaceller
BRPI0907624A2 (pt)	2016-08-16	tratamento e prevenção de doenças cardíacas usando duas ou mais isoformas do fator de crescimento de hepatócito
EP2068702A4 (en)	2012-10-17	SYSTEM AND TECHNIQUES BASED ON PULSE OXYMETER FOR DERIVING CARDIAC AND RESPIRATORY PARAMETERS FROM EXTRA-THORACIC BLOOD FLOW MEASUREMENTS
BR112012003462A2 (pt)	2016-02-23	"composto, composição farmacêutica, e, método para tratar um paciente tendo uma condição mediada pela proteína quinase."
BR112012003464A2 (pt)	2015-09-08	composto, composição farmacêutica, usos de uma composição farmacêutica e de um composto, e, método para tratar uma doença ou um distúrbio."
EP4374860A3 (en)	2024-08-07	Use of pimobendan for the reduction of heart size and/or the delay of onset of clinical symptoms in patients with asymptomatic heart failure due to mitral valve disease
ATE510536T1 (de)	2011-06-15	Verwendung von 2,5-dihydroxybenzol-derivaten zur behandlung von reaktiven gewebeerkrankungen
EP2478901A3 (en)	2012-11-14	Neurogenic compounds
BRPI0920170A2 (pt)	2016-06-21	métodos para diminuir a quantidade de partículas ldl pequenas e densas e de níveis de triglicerídeos e ldl no sangue em um humano, e para identificar um indivíduo candidato para tratamento com um composto ou um sal, prodroga ou isômero do mesmo, composto ou um sal, prodroga ou isômero do mesmo, e método.
WO2015157345A3 (en)	2016-03-31	Bioenergetic profiling of circulating blood cells and systems, devices, and methods relating thereto
EP2716285A3 (en)	2014-09-03	New method for identifying compounds useful for treating and/or preventing diseases associated with bone loss
WO2007106369A3 (en)	2007-11-01	Case-finding systems and methods
EP1838260A4 (en)	2011-05-25	SYSTEM AND METHOD FOR TREATMENT OF CARDIAC TISSUE
EP1952833A4 (en)	2013-06-05	CLOSED TYPE BLOOD STORAGE TANK AND EXTRACORPORAL BLOOD CIRCULATION SYSTEM USING SAID TANK
BRPI0612624A2 (pt)	2016-11-29	métodos para tratar doença vascular em um humano, e para prevenção e/ou tratamento de uma doença induzida por trombose ou uma doença induzida por tromboembolismo em um humano, e, uso de um composto
WO2008006187A3 (en)	2009-02-12	Protein complexes for prevention and treatment of diseases with angiogenesis disorders